Tarsus Pharmaceuticals (TARS) Equity Income (2021 - 2024)
Tarsus Pharmaceuticals (TARS) recorded quarterly Equity Income of -$6000.0 in Q2 2024, up 98.97% quarter-over-quarter from -$585000.0 in Q1 2024, and down 140.0% on a YoY basis from $15000.0 in Q3 2023.
Tarsus Pharmaceuticals (TARS) Equity Income (2021 - 2024) Analysis & Trends
Tarsus Pharmaceuticals' Equity Income history runs 4 years deep, the most recent figure standing at -$6000.0 for Q2 2024.
- In Q2 2024, Equity Income fell 140.0% year-over-year to -$6000.0; the TTM figure through Dec 2024 stood at -$591000.0 (down 328.19% YoY), while the FY2024 annual figure was -$591000.0, down 328.19% from the prior year.
- Equity Income was -$6000.0 for Q2 2024 at Tarsus Pharmaceuticals, up from -$585000.0 in the prior quarter.
- In the past five years, Equity Income ranged from a high of $420000.0 in Q4 2023 to a low of -$591000.0 in Q4 2021.
- Historically, Equity Income has averaged -$108272.7 across 4 years, with a median of -$65000.0 in 2023.
- The sharpest annual moves came in 2023 and 2024: Equity Income surged 624.14% in 2023, then plunged 800.0% in 2024.
- A 4-year view of Equity Income shows it stood at -$591000.0 in 2021, then soared by 109.81% to $58000.0 in 2022, then soared by 624.14% to $420000.0 in 2023, then tumbled by 101.43% to -$6000.0 in 2024.
- The last three Equity Income figures came in at -$6000.0 (Q2 2024), -$585000.0 (Q1 2024), and $420000.0 (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 235,807.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Tarsus Pharmaceuticals | 2.71 Bn | 2.61 Bn | 152.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -6,000.00 |
| Mar 31, 2024 | -585,000.00 |
| Dec 31, 2023 | 420,000.00 |
| Sep 30, 2023 | -111,000.00 |
| Jun 30, 2023 | 15,000.00 |
| Mar 31, 2023 | -65,000.00 |
| Dec 31, 2022 | 58,000.00 |
| Sep 30, 2022 | -13,000.00 |
| Jun 30, 2022 | -121,000.00 |
| Mar 31, 2022 | -192,000.00 |
| Dec 31, 2021 | -591,000.00 |